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Summary We wished to develop and validate a simple linear analogue self-assessment (LASA) scale to assess utility values in multicentre,
multicultural breast cancer trials. We compared two variants of a LASA scale (score range 0-100) with different anchoring points [perfect
health to worst possible health (subjective health estimation, SHE) and perfect health to death (SHED)] in 84 patients with advanced breast
cancer. Feasibility was explored in the first 48 patients interviewed. Values from the LASA scales were compared with each other and with a
time trade off (TTO) interview. Scores from the two LASA scales were highly correlated (r = 0.8, P < 0.0001, Spearman). The relationship
between TTO interview and SHE was confirmed with tests for trend across ordered groups (linear-trend test P < 0.001). Most patients
preferred SHE to SHED. SHE scores (in which high scores indicate high-health-state values) were significantly different by type of treatment,
time from diagnosis and age. Thus, significantly different mean SHE scores were obtained from patients receiving no treatment or hormone
therapy, mild and intensive chemotherapy (ANOVA P= 0.03) and from patients with diagnosis 2 years, 2-5 years, 5-10 years and more than
10 years before interview (ANOVA P = 0.02). Older patients (> 56 years) had a lower mean on the SHE scale (53 vs 61; ANOVA P = 0.04).
Wefound that the two versions of the LASA scale were equivalent for clinical purposes. SHE appeared to provide a feasible, patient-preferred
and valid alternative to lengthy TTO interviews in assessing the value patients attach to their present state of health in large-scale cancer
clinical trials.
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Clinical trials increasingly measure patients' subjective experience
as well as duration oflife. Two different approaches to quantitative
assessment of patients' subjective experience have emerged:
health-related quality of life (HRQL) and utility. The concept of
quality of life has its roots in psychosocial science and includes
physical, emotional, social and sometimes also cultural and spiri-
tual components ofsubjective experience. Multidimensional scales
have been developed to allow patient self-assessment ofHRQL.
The concept of utility is derived from economical science.
Utilities may be defined as patient-stated preferences for various
health states under conditions of uncertainty. Utility values, when
based on both subjective experience and HRQL, may change over
time. In medical applications, a utility value is associated with a
certain health state. It is usually denoted by a value between 0
(equivalent to death) and 1 (perfect health). Various methods have
been used to measure utilities (Torrance, 1976, 1987; Feeny et al,
1989; Kaplan et al, 1990). In the 'standard gamble' method, an
interviewer asks subjects to make a choice between various proba-
bilities of survival for different options. In the 'time trade-off'
(TTO) approach, subjects assess equivalence between a shorter
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length oflife in perfect health and a longer period in the particular
health state. Utility values are more easily integrated than are
HRQL scores with the conventional end points to allow weighted
comparison of times spent in different health states. Their disad-
vantage, particularly in large clinical trials, is the amount of time
and resources required (Weeks, 1991; Guyatt et al, 1993). Previous
attempts to use simple rating scales as measures ofutility (Ross et
al, 1978; Sutherland et al, 1983; Read et al, 1984; Torrance, 1986;
Noack, 1990) have shown varying degrees of agreement with the
standard gamble and ITO methods.
The Q-TWiST model developed by Gelber and Goldhirsch
(1986, 1989) is autility-based assessment that divides the life-span
ofthe patients from thebeginning ofadjuvant treatment until death
into three time segments corresponding to distinct health states:
TOX (time with toxicity from treatment), TWiST (time without
symptoms of treatment or disease) and REL (time from relapse
until death). TOX and REL are weighted by arbitrary utility coeffi-
cients and added to TWiST to reach an overall assessment of
different treatment groups. The shortcoming of the Q-TWiST
method thus far is that utility coefficients for the different health
states have been assigned arbitrarily.
The International Breast Cancer Study Group (IBCSG) is a
large co-operative group that conducts clinical trials of adjuvant
treatments in patients with early breast cancer. Since 1985, we
have developed methods to assess HRQL and to integrate utilities
with the conventional end points of disease-free and overall
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survival in IBCSG trials (i.e. Q-TWiST). To estimate HRQL, we
adapted the patient-rated Linear Analogue Self Assessment
(LASA) scales, assessing four broad components ofHRQL: phys-
ical well-being, appetite, emotional well-being and coping. HRQL
data from the first two large trials yielded clinically meaningful
results (Hurny et al, 1996).
Although arbitrary utility coefficients in the Q-TWiST model
can provide a useful decision aid for threshold analysis (Cole et al,
1995; Gelber et al, 1996), we wished to assess patients' own utili-
ties directly in a manner suitable for large international trials. As
the HRQL assessments in our trials use a LASA format, we
designed two LASA scales for health state estimation. As a first
step we compared the two scales, then we validated the preferred
scale by direct comparison with time trade-offquestions.
PATIENTS, METHODS AND PROCEDURES
Patients and procedures
We studied ambulatory patients with metastatic or inflammatory
breast cancer seen for treatment or routine check-ups at university
or cantonal hospitals in three language areas of Switzerland.
Eligible patients were aged 20-75 years, had experienced
chemotherapy, had an ECOG performance status of0-3, were free
ofpsychiatric illness, were able to respond to interview questions
in one of the three study languages and gave informed consent.
Ethical committee approval was obtained for each participating
institution.
Medical data were abstracted from the medical records after
obtaining informed consent from the patient, but before interview.
Atthe time ofthe interview, sociodemographic data were collected
from patients. Patients first completed the LASA questionnaire,
then the TTO interview.
Two LASA scales were prepared as utility measures. First, in
order to cover the entire range of theoretical utilities, the SHED
scale used 'perfect health' and 'death' as descriptions of the ends
of the scale. Because of concern that use of the word 'death'
might cause distress, a second LASA scale (the SHE scale) used
(perfect health' and 'worst possible health' (for full wording see
Appendix 1). The time frame specified 'the rest of your life'.
Translations into the three required languages followed the proce-
dures of forward and backward translation suggested by the
EORTC quality oflife working group (unpublished manuscript by
EORTC translation work group, 1992), using professional transla-
tors. The final translations were checked for linguistic equivalence
by clinicians involved in the study who were fluent in the
languages concerned and familiar with the concepts ofhealth-state
assessment. The questionnaire form contained the SHED and
SHE scales, together with four LASA scales forthe HRQL indica-
tors physical well-being, mood, appetite and coping (Hurny et al,
1992, 1993).
In the time trade-off questions (TTO), patients were asked to
trade between 12 months in their current state of health and an
equal or smaller amount oftime (12, 11, 9, 6, 3, 1 or 0 months) in
perfect health (Weeks, 1991). (The full text of the TTO questions
is given in Appendix 2.) As our patients were severely ill, 'the rest
of your life' was about 1 year, which corresponded to the time-
frame in the TTO question. According to our hypothesis, there
should have been a close correspondence between the worth
attached to the current health state in the 1T0 and the rating scale.
After completion of the TTO questions, the patients from the
two German-speaking centres were asked about their reaction to
the investigation. Nine questions were asked on patients' general
reaction to the previous questioning, emotional and other difficul-
ties in answering the TTO questions and thoughts going through
their minds when placing a mark on the SHE and SHED scales.
Patients' answers to these nine questions were categorized by two
ofthe authors (BvW, MB) by a consensus rating. Patients from the
other language areas were not formally assessed concerning their
reaction to the investigation but were encouraged to give their
opinion about the interview and the topic of investigation at the
end of the TTO questions. Interviews were conducted by physi-
cians, by a psychologist and by research nurses. All interviewers
were provided with a written protocol on the study purpose and
data collection procedures (including visual aids) to standardize
the assessments in the different centres and were personally
instructed and trained in TTO interviewing by one of the authors
(BvW orJB).
In summary, the study was performed in two steps: first, in
centres in the German-speaking area, TTO interviews were
performed; SHED, SHE and HRQL scales were filled out; and the
reaction to the investigation was assessed. Then, the investigation
was expanded to centres in the French- and Italian-speaking areas,
including TTO interview, SHE and HRQL assessment only.
Statistical analysis
In order to determine whether the two scales could be used inter-
changeably, at least so that SHE could replace SHED with suffi-
cient accuracy for the intended purpose of measurement, SHED
and SHE were checked for 'comparable answers/scores' as
suggested by Altman and Bland (1983). The hypothesis of zero
bias was examined by a signed-rank test (Snedecor, 1989). The
overlapping (ovl) coefficient (range 0-1) was also used to assess
the practical meaning of differences between the SHED and the
SHE distributions (Bradley, 1985; Inman and Bradley, 1989) and
to complement comparability evaluation. Comparability of scales
was tested both overall and separately by centre. The Spearman
correlation coefficient between SHED and SHE scores was used to
test the construct validity ofSHE.
The TTO questions gave an ordinal categorical response format.
We expected that patients with lower (worse) values on the SHE
scale would be more prepared to give up time in their current state
of health in exchange for perfect health. They would hence be
willing to trade shorter times in perfect health for the 12 months
in their current state of health. A Wilcoxon-type test for trend
proposed by Cuzick (1985) was used to provide evidence for the
validity ofthe SHE scale against TTO. We also tested for a linear
trend in all HRQL LASA scales across TTO answers.
The impact of biomedical and sociodemographic factors on
SHE was analysed with ANOVA.
A powertransformation ofLASA score to1T0 utility scores has
been proposed for a 'death' to 'perfect health' scale (Torrance,
1976) and for 'worst imaginable health' to' best imaginable health'
scale (van Busschbach, 1994). We therefore estimated theparameter
alpha of the model SHE = 1 - (1 - TTO)alpha from a straight-line
regression analysis through the origin of log (1 - SHE) on
log(1 -11T0) as suggestedby Stiggelboutetal (1996). Models were
fitted, using least squares regression, at the individual level, treating
LASA-worst health (SHE) both as a dependent (SHE-1TO) and as
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an independent variable (TTO-SHE). The aims were to compare our
results with the published data and to verify how to predict TTO
from SHE.
Statistical analyses were carried out with STATA.
RESULTS
Patient accrual
Between October 1992 and January 1993, a total of 83 potentially
eligible patients were reported in the German-speaking area (two
centres). Ofthese, 24 patients (29%) refused, the main reasons for
refusal being low performance status andreluctance to speak about
illness-related topics in an interview, seven (8%) could not be
interviewed for logistical reasons and four (5%) had to be excluded
because they did not have metastatic disease, leaving
48 (58%) evaluable patients from the German-speaking area.
Between June 1993 and September 1994, the investigation
continued in the French and Italian areas. Overall, we investigated
84 evaluable patients, 48 (57%) from German-, 30 (36%) from
French- and six (7%) from Italian-speaking areas. Table 1 summa-
rizes patient characteristics.
Table 1 Patient characteristics
Frequency Per cent
Age (years)
45 and younger 19 23
46-55 27 32
56-65 24 29
66 and older 14 17
Performance status
0 39 46
1 28 33
2-3a 17 20
Nodal status (diagnosis)
Positive 64 76
Negative 16 19
Unknown 4 5
ER status (diagnosis)
Positive 53 63
Negative 16 19
Unknown 15 18
First diagnosis
Within last 2 years 11 13
Within last 5 years 36 43
> 5 years, < 10 years ago 26 31
> 10 years ago 11 13
First recurrence
Within last 6 months 17 20
Within last 2 years 30 36
> 2 years ago 37 44
Chemotherapy at interview time
None 36 43
Mildb 15 18
Intensiveb 33 39
Total 84
a Including six patients with unknown performance status. bSee text for
definition of 'mild' or 'intensive'. ER, oestrogen receptor.
Feasibility and acceptability
All the questions were generally well accepted. Answers
concerning the reaction to the investigation were available from 45
(94%) ofthe 48 patients interviewed in the German-speaking area
(two patients declined this evaluation and one patient responded
only in part). The answers of5 out of45 patients could notbe rated
into the predefined categories. Thirty patients (63%) described the
interview in general as being no problem or interesting. For 17
patients, the questions were difficult, and eight patients judged
them as causing distress (some of these had also described the
questionnaire overall as interesting).
Most patients (n = 34, 71%) classified the LASA questions on
physical well-being, appetite, mood and coping as easiest, while
either SHE/SHED ortheTTO questions werejudgedeasiestby ten
patients (21%) and, for one patient (2%), no questions could be
classified as easiest. For 15 patients (31%), the TTO question was
the most difficult one. Only seven patients (15%) found SHE or
SHED most difficult, but the majority described the SHED as
being more difficult than the SHE. Two patients (4%) did not
classify any question as most difficult.
Subjective responses to SHE and SHED
We asked the same 45 responding patients about the thoughts that
crossed their mind in placing the marks on the SHED and SHE
scales. Three types of responses were obtained. Twenty-seven
4a
0
0
w
I
cn)
100-
90-
80-
70-
60-
50-
40-
30-
20-
10-
0-
50-
aD 30-
0 co)
c 10- a
a)
CD-3-
C.)
C -30- a
a -50
-
-70-
0 10 20 30 40 50 60 70 80 90 100
SHE scale
0 0a 0o ,0 0o 0 a 0
o a
0 20 40 60 80 100
Average of scales
Figure 1(A) Comparison of SHED and SHE scales. An 'equality' line (same
score on both scales) is drawn to facilitate visual comparison. (B) Difference
between SHED and SHE scales plotted against theirjoint mean. No
significant relationship was detected between the size of score and the
difference befween SHE and SHED
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Table 2 TTO: comparison of mean answers on SHE with points of equivalence between 12 months in current health and O-12 months in perfect health
TTO points of equivalence between SHE SHE
current and perfect health n =83 (TTO ungrouped) (HTO grouped)
Mean
Mean s.d.
12 months in current = 12 months in perfect health (U= 1) 37 68.0 68.0 25.4
12 months in current = 11 months in perfect health (U= 0.90) 12 56.7
54.8 19.5
12 months in current = 9 months in perfect health (U= 0.75) 10 52.6
12 months in current = 6 months in perfect health (U= 0.50) 11 48.6
47.2 24.6
12 months in current = 3 months in perfect health (U= 0.25) 7 44.9
12 months in current = 1 month in perfect health (U= 0.08) 3 55.3
36.8 35.1
12 months in current = 0 months in perfect health (U = 0) 3 18.3
P-value (Cuzick test) < 0.001 < 0.001
U, utility.
patients thought about their present state of health in a realistic
way when placing their marks on the scale, and that they felt
neither dead norcompletely healthy. The means in this group were
60.5 and 67.4 for SHE and SHED respectively. Wishful thinking
was evident in eight patients who would have liked to place the
mark at the 'perfect health' end of the scale because they wished
so much to be healthy. This influenced theirplacement ofthe mark
equally as strongly as theirknowledge that they were not in perfect
health. Their mean scores on the health-state-estimation questions
were higher than in the 'realistic' group (70.8 for SHE and 70.9 for
SHED). Seven patients specifically stated that they did not like the
word 'death' appearing on the anchor point of one of the LASA
scales, did not want to think about anything to do with death and
therefore hadplaced their mark as far away from the 'death' end of
the scale as possible. This was reflected in substantially higher
means for SHED (77.7) compared with SHE (63.9). The
remaining three patients gave other answers, such as general state-
ments about illness or comments unrelated to the questions.
Comparison of SHE with SHED
To test construct validity, we first investigated the comparative
qualities ofSHE and SHED in patients from the German-speaking
area. The two scales showed a strong correlation (Spearman r =
0.80, P < 0.0001; Figure IA). An equality line (same scores on
both scales) is drawn to facilitate visual comparison. The mean
values were 65.9 (s.d. 20.3) for SHED and 61.3 (s.d. 23.9) for
SHE. The median values were 65 (range 18-100) for SHED and
62 (range 3-99) for SHE. A plot of the difference between
methods against their mean is shown in Figure lB. The lack of
agreement between the two scales was apparently worse in
patients reporting higher SHED scores. However, the between-
method difference (SHED - SHE) was not significantly related to
the absolute score [(SHED + SHE)/2, r = 0.25]. The mean of the
individual differences (SHED - SHE, 'relative bias') was 4.7 (95%
confidence interval - 0.1-9.3) and its standard deviation (estimate
of 'error') was 16.1. The null hypothesis of a zero bias was not
rejected (signed-rank test P = 0.09). In this context, a difference of
less than five points in scales ranging from 0 to 100 would not be
considered clinically important. The scales showed high overlap-
ping coefficients, > 0.99 if the variances were assumed equal and
0.89 if they were allowed to differ, indicating substantial overlap
ofthe two distributions.
Except for generally lower scores at one centre, which could be
attributed to more patients with poor performance status, the
results were similar across both centres investigated.
Comparison of SHE with TTO
Given the strong correlation of the two scales, the minimal and
presumably clinically not relevant differences observed, and the
betteracceptability ofthe SHE scale, wedecided to drop the SHED.
For further validation and clinical use, we compared the SHE scale
with TTO scenarios. In the following analyses, patients' data from
all language centres (German, French and Italian speaking) were
included. The comparison of SHE scores from the German and
other centres showed that the scoring behaviour in all three
language areas was sufficiently similar tojustify merging the data.
Table 2 shows mean SHE scores for each possible value ofTTO
and for grouped values of TTO (12 vs 9 or 11 vs 3 or 6 vs 0 or 1
month) corresponding to 'perfect, good, fair andpoor' utilities. The
test for trend was highly significant in both analyses (P < 0.001).
Influence of patient characteristics and treatment on
SHE
SHE scores were significantly different in patient groups according
to time since diagnosis (see Table 1). The mean SHE scores (s.d.)
were 61.7 (20.0) for 11 patients with diagnosis in the previous
2 years, 52.3 (28.8) with diagnosis between 2 and 5 years (36
patients), 54 (23.5) with diagnosis between 5 and 10 years (26
patients) and 78.9 (18.5) with diagnosis more than 10 years before
interview ( 1 patients) (ANOVA P = 0.02). Age reached borderline
significance with older patients (> 56 years, 38 patients), showing
lowermean values (53 vs 61) on the SHE scale (ANOVA P = 0.04).
Treatment type also affected SHE scores. Mean score for 36
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patients receiving hormonal or no treatment was 62.8 (23.4), while
it was 65.1 (22.1) for 15 patients receiving mild chemotherapy and
48.3 (28.5) for 33 patients receiving intensive chemotherapy
(ANOVA P = 0.03).
Comparison of SHE with HRQL LASA scores
In the total sample, in order to assess discriminant validity of SHE
(i.e. whether this scale assesses something substantially different
than the other LASA scales), correlations and tests for trend were
also performed for all HRQL scales (physical well-being, appetite,
mood and coping) with TTO to compare the strength oftheir asso-
ciations. There was no significant association/trend between the
TTO and the LASA scales for mood and coping. Although the
association between SHE and TTO was stronger (linear-trend test
P < 0.001), the scales for physical well-being and appetite also
showed a significant linear-trend association with TTO (P = 0.03
and 0.01 respectively). Patients seemed to be more willing to trade
time in current health when theirphysical condition was less good.
The correlation between physical well-being or appetite and SHE
was moderate (r = 0.51 and 0.42 respectively).
Transformation of SHE-TTO
In a final step, we explored a power transformation of SHE scores
to TTO utility scores (SHE-TTO) and vice versa (TTO-SHE). In
the 48 German-speaking patients, and in contrast to others
(Stiggelbout et al, 1996), we obtained a satisfactory fit at the indi-
vidual patient level (r2 = 0.65) for the SHE-TTO. Our estimate of
alpha was 0.42 (s.d. 0.05), similar to a previous estimate of 0.47
(van Busschbach, 1994) for the same type of scale. Treating TTO
as the dependent variable (TTO-SHE), we obtained an alpha of
1.54 (s.d. 0.17).
DISCUSSION
Assigning values to individual health states is important to the
assessment of many medical interventions. Both TTO and rating
scales have been used in clinical studies. Coates and Simes (1992),
Ashby et al (1994) and McQuellon et al (1995) studied patients
with breast cancer. Stiggelbout et al (1994) and Boyd et al (1990)
have studied disease-free testicular and gastrointestinal cancer
patients. Feeny et al (1992) interviewed survivors of childhood
cancer. Consecutive cancer patients were studied by Kiebert et al
(1993) and Tsevat et al (1990). One of the main problems in
obtaining evaluations of particular health states from persons not
afflicted by the condition is finding a reliable and valid description
of the health states (Llewellyn et al, 1982; Gerard et al, 1993;
Ashby et al, 1994). Our purpose was limited to describing each
patients' current health status, so this difficulty did not arise.
TTO and standard-gamble interviews are not feasible in the
setting oflarge clinical trials, hence self-administered scales are an
attractive alternative, if they work. In the present study, we have
provided good evidence that the SHE scale is a valid and feasible
method to assess the value patients attribute to their current state of
health. As we expected, the SHE scale, anchored with worst
health, was more acceptable to patients than SHED, although the
death anchor point on SHED is more closely similar to classical
utility. In fact, the two scales yielded closely similar values,
indicating construct validity for SHE (Mummendey, 1987,
pp. 104-109). Criterion validity is supported if the individual
patient's answer on the scale corresponds with relevant outside
criteria, assessed independently of the values given on the health
estimation scale (Mummendey, 1987, pp. 81-83). We have shown
criterion validity by demonstrating plausibly different mean values
of SHE for groups of patients with different treatments and age.
Different times since diagnosis as an indication of aggressiveness
of disease also had a substantial impact on SHE scores. However,
the trend ofthis association was not linear and needs further study.
Our results showed that the answers that patients gave on both
scales (SHE and SHED) were comparable.
To determine whether SHE measures something different to the
other LASA scales used in the HRQL questionnaire, we compared
all LASA scales with TTO answers. As the relationship between
SHE and TTO was stronger than between the other LASA scales
and TTO, this would give an indication of discriminant validity of
SHE (Mummendey, 1987, pp. 84-85; Streaner and Norman, 1995).
The more time in their current health state that patients were
prepared to trade for a lesser amount oftime in perfect health, the
lower were their health-state-estimation values on the SHE scale.
This linear trend was highly significant. Our estimate ofalpha for
the SHE-TTO transformation (0.42, s.d. 0.05) was similar to that
obtained by van Busschbach (1994), who also used an anchor of
'worst imaginable health' rather than 'death', but lower than the
value proposed by Torrance (1986) and by Stiggelbout et al
(1996); these two studies used a scale anchored by death and
perfect health. Thus, the appropriate value ofalpha for transforma-
tion may depend on the type of scale used, but both types of scale
seem to allow transformation from LASA to TTO scores, so that
patient self-assessment scores can be transformed for use in deci-
sion models. Additional research is needed to explain the observed
power relationship (including the validity of the transformation).
Different disease settings, being on treatment or not and other
factors could be influencing this power function. Before using
such a transformation, sensitivity analyses should be carried out
and careful evaluation of small changes in the coefficient on the
TTO should be performed.
While SHE had the most consistent relationship with FTO, a
significant association was also found between the physical
aspects of HRQL and the answers to the TTO questions. Patients
seemed to be more prepared to trade some time in their current
state ofhealth when their physical condition was less good.
An open issue with regard to SHE is its subjective meaning to
the individual patient filling in the scale. This issue is relevant
generally in HRQL assessment and has been addressed by several
authors (Schag et al, 1984; Slevin et al, 1988; Jenkins, 1992). We
attempted to shed some light on this by asking patients about their
thoughts when completing the scale. Their answers indicated some
heterogeneity, as suspected by Jancik and Yates (1986). However,
a large proportion of our patients scored the scale on the basis of
thoughts about their current health.
Denial is a common coping style among cancer patients; this
may affect SHE scores, as could be seen from the much higher
means on SHE for the unrealistically optimistic patients and the
divergence between SHE and SHED for patients who reacted
unfavourably to the concept ofdeath on the SHED scale. This may
also apply to other self-assessment HRQL scales.
Our patients with metastatic breast cancer assessed their health
state as relatively high. More than half of the patients would have
traded no or only a very short time of their current condition for
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time in perfect health. This strong weighting of survival time per
se is also reflected by the tendency to readily accept very discom-
forting health states with small gains in survival time observed in
other studies with breast cancer patients (Coates and Simes, 1992;
McQuellon et al, 1995).
We conclude from our study of the SHE scale in a limited
sample of patients with metastatic breast cancer from three
cultures that this simple scale is a feasible and valid method to
assess the value patients attribute to their current state of health,
especially for large-scale cancer clinical trials including patients
from various countries and cultures. We have provided strong
evidence that it can be transformed to give an adapted concept of
utility, which can be incorporated as an approximation into
quality-adjusted survival analysis, such as QALYs (Miyamoto,
1985; Carr-Hill, 1989; Mehrez, 1989) or Q-TWiST (Gelber and
Goldhirsch, 1986; Goldhirsch et al, 1989). As SHE is patient
derived, it is arguably preferable to arbitrary utility values assigned
by investigators. We are currently assessing subjective health esti-
mations by SHE in the large-scale international adjuvant breast
cancer trials of the International Breast Cancer Study Group, in
parallel with our conventional HRQL indicators. These studies
will give us the opportunity to further investigate this scale, with
special emphasis on cross-cultural factors, sensitivity to changes
over time from diagnosis and the impact of different
treatments and ofdisease relapse.
ACKNOWLEDGEMENTS
We would like to thank the physicians, nurses and patients who
participated in the study and L Bacchus, M Tomamichel and Mrs
Warrick who interviewed patients in St Gallen, Lugano and
Geneva. We are grateful to M Castiglione, Scientific Director
of the SAKK/SIAK, for providing the infrastructure of the
Coordinating Centre. We extend our special thanks to S
Pampallona, G Jones, R Gelber and A Goldhirsch for reviewing
and commenting on earlier versions ofthis paper.
REFERENCES
Altman DG and Bland JM (1983) Measurement in medicine: the analysis of method
comparison studies. Statistician 32: 307-317
Ashby J, O'Hanlon M and Buxton MJ (1994) The time trade-offtechnique: how do
the valuations of breast cancer patients compare to those ofother groups? Qual
Life Res 3: 257-265
Boyd NF, Sutherland H, Heasman K, Tritchler D and Cummings B (1990) Whose
utilities for decision analysis? Med Decis Making 10: 58-67
Bradley EL (1985) Overlapping coefficient. In EncVclopedia ofStatistical Sciences
Vol. 6, Kotz S and Johnson NL. (eds), pp. 546-547, Wiley: New York
Carr-Hill R (1989) Background material for the workshop on QUALYs.
Assumptions ofthe QUALY procedure. J Sci Med 29: 469-477
Coates A and Simes RJ (1992) Patient assessment ofadjuvant treatment in operable
breast cancer. In Introducing New Treatmentsfor Cancer: Practical, Ethical
and Legal Problems. Williams CJ. (ed.), pp. 447-458. John Wiley & Sons:
New York
Cole BF, Gelber R and Goldhirsch A (1995) Comparing treatments using quality-
adjusted survival: the Q-TWiST method. Amt Statistician 49: 161-169
Cuzick J ( 1985) A Wilcoxon-type test for trend. Stat Med 4: 87-90
Feeny DH and Torrance G (1989) Incorporating utility-based quality-of-life
assessment measures in clinical trials. Two examples. Med Care 27 (suppl.):
S190-S204
Feeny DH and Furlong W, Barr R, Torrance GW, Rosenbaum P and Weitzman S
(1992) A comprehensive multiattribute system for classifying the health status
of survivors ofchildhood cancer. J Clin Otncol 10: 923-928
Gelber RD and Goldhirsch A (1986) A new endpoint for the assessment ofadjuvant
therapy in postmenopausal women with operable breast cancer. J Cliti Onicol 4:
1772-1779
Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F,
Gray R, Gordon NH, Bengtsson NO and Sevelda P (1996) Adjuvant
chemotherapy plus tamoxifen compared with tamoxifen alone for
postmenopausal breast cancer: meta-analysis ofquality-adjusted survival.
Lancet347: 1066-1071
Gerard K, Dobson M and Hall J (1993) Framing and labelling effects in health
descriptions: quality adjusted life years for treatment of breast cancer. J Clin
Epidemiol 46: 77-84
Goldhirsch A, Gelber R, Simes J, Glasziou P and Coates A for the Ludwig Breast
Cancer Study Group (1989) Costs and benefits ofadjuvant therapy in breast
cancer: a quality-adjusted survival analysis. J Clini Oncol 7: 36-44
Guyatt GH, Feeny DH and Patrick DL (1993) Measuring health-related quality of
life. Ann Intern Med 118: 622-629
Hurny C, Bernhard J, Gelber R, Coates A, Castiglione M, Isley M, Dreher D,
Peterson H, Goldhirsch A and Senn HJ for the International Breast Cancer
Study Group (1992) Quality of life measures for patients receiving adjuvant
therapy for breast cancer: an international trial. Eur J Cancer 28: 118-124
Horny C, Bernhard J, Bacchi M, Van Wegberg B, Tomamichel M, Speck U, Coates
A, Castiglione M, Goldhirsch A and Senn HJ for the Swiss Group for Cancer
Research and the International Breast Cancer Study Group (1993) The
perceived adjustment to chronic illness scale (PACIS): a global indicator of
coping for operable breast cancer patients in clinical trials. Supp Care Cancer
1: 200-208
Hurny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD,
Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A and Senn
HJ for the International Breast Cancer Study Group (1996) Impact ofadjuvant
therapy on quality of life in women with node-positive operable breast cancer.
Lanicer 347: 1279-1284
Inman HF and Bradley EL Jr (1989) The overlapping coefficient as a measure of
agreement between 2 probability distributions and point estimation ofthe
overlap of two normal densities. Commun Stat Theors Methodol 18:
3851-3874
Jancik R and Yates JW (1986) Quality of life assessment of cancer patients:
conceptual and methodological challenges and constraints. Cancer Bull 38:
217-222
Jenkins D (1992) Assessment ofoutcomes of health intervention. Soc Sci Med 35:
367-375
Kaplan RM and Anderson JP (1990) The general health policy model: an integrated
approach. In Quality ofLife Assessments in Clinical Trials Spilker B. (ed.),
pp. 131-149. Raven Press: New York
Kiebert G, Stiggelbout AM, Leer JW, Kievit J and De Haes HJ (1993) Test-retest
reliabilities of two treatment preference instruments in measuring utilities. Med
Decis Making 13: 133-140
Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, Ciampi A, Till JE and Boyd NF
(1982) The measurement ofpatients' values in medicine. Med Decis Making 2:
449-462
McQuellon RP, Hyman BM, Hoffman SL, Russel G, Craven B and Yellen S (1995)
Patient preferences for treatment of metastatic breast cancer: a study of women
with early-stage breast cancer. J Clin Oncol 13: 858-568
Mehrez A and Gafni A (1989) Quality-adjusted life years, utility theory and healthy-
years equivalents. Med Decis Making 9: 142-149
Miyamoto JM and Eraker StA (1985) Parameter Estimates for a QUALY utility
model. Med Decis Making 5: 191-213
Mummendey HD (1987) Die Fragebogen-Methode. Hogrefe: Gottingen
Noack H (1990) Gemeinsame Betrachtung von Lebenszeit und Lebensqualitat,
Poster auf der Arbeitstagung 'Erfassung von Lebensqualitat in der Onkologie',
Heidelberg, 10-12 Mai 1990
Read JL, Quinn RL, Berwick DM, Fineberg HB and Weinstein M (1984)
Preferences for health outcomes. Comparison of assessment methods. Med
Decis Making 4: 315-329
Ross R and Kind P (1978) A scale of valuations of states of illness: is there a social
consensus? IntJEpidemiol 7: 347-358
Schag CC, Heinrich RL and Ganz PA (1984) Karnofsky performance status
revisited: reliability, validity and guidelines. J Clin Oncol 2: 187-193
Slevin ML, Plant H, Lynch D, DrinkwaterJ and Gregory WM (1988) Who should
measure quality of life, the doctor or the patient? BrJ Catncer 57: 109-112
Snedecor GW and Cochran WG (1989) Statistical Methods. 8th edn. Iowa State
University Press: Ames, IA
Stiggelbout AM, Kiebert GM, Kievit J, Leer JWH, Stoter G and De Haes JC (1994)
Utility assessment in cancer patients: adjustment of time tradeoff scores for the
utility of life years and comparison with standard gamble scores. Med Decis
Making 14: 82-90
Stiggelbout AM, Eijkemans MI, Kiebert GM, Kievit J, Leer, JW and De Haes HI
(1996) The 'utility' of the visual analog scale in medical decision making and
British Journal of Cancer (1998) 77(6), 985-991 C) Cancer Research Campaign 1998Subjective health estimations in breast cancerpatients 991
technology assessment. Is it an alternative to the time trade- off? IntJ Technol
Assess Health Care 12: 291-298
Streaner and Norman (1995) Health Measurement Scales. A Practical Guide to their
Development and Use. 2nd edn. University Press: Oxford, UK
Sutherland H, Dunn V and Boyd N (1983) Measurement of values for states of
health with linear analog scales. Med Decis Making 3: 477-487
Torrance G (1976) Social preferences for health states: an empirical evaluation of
three measurement techniques. Socio-Economic Planning Sciences 10:
129-136
Torrance G (1986) Measurement ofhealth state utilities for economic appraisal. A
review. JHealth Econ 5: 1-30
Torrance G (1987) Utility approach to measuring health-related quality oflife.
J Chron Dis 40: 593-600
Tsevat J, Dawson N and Matchar D (1990) Assessing quality oflife and preferences
in the seriously ill using utility theory. J Clin Epidemiol 43 (suppl.): 73S-77S.
Van Busschbach J (1994) De validiteit van QUALY's (The validity ofQUALY's).
PhD thesis. Erasmus University Rotterdam, Sanders Instituut: Rotterdam
Weeks J (1991) Utilities as a measure ofquality oflife in cancer patients. Study
documentation for an investigation conducted forthe Dana-Farber Cancer
Institute, Boston
APPENDIX I
Utility and quality of life LASA scales
Patient's name: Date: Center: Int.
Please spare a moment to answer the following questions. Your
information will be treated as strictly confidential. Thank you for
replying.
Please place a vertical line according to how you rate the
following aspects overall, for the entire period since your last full
clinical assessment.
Example:
Tiredness:
None A lot
Physical well-being:
Good Lousy
Mood:
Happy Miserable
Imagine you had to spend the rest of your life in your current
condition. How would you rate such a life between:
Perfect health Death
Appetite:
Good None
How much effort does itcostyou to cope with yourillness:
No effort at all A great deal
Imagine you had to spend the rest of your life in your current
condition. How would you rate such a life between:
Perfect health Worst possible health
APPENDIX 2
Time trade-off interview
Patient's name: Date: _ Center: Int.
(Instructions to Interviewer are always in brackets.)
1. Comprarison of health state today with varying amounts of
survival time in perfect health (Interview developed by Jane
Weeks, Dana-Farber Cancer Institute, Boston).
Introduction: I am now going to ask you a few questions dealing
with how you feel about your current state ofhealth. Please realize
that these questions do not mean that anyone knows how long you
will live, we simply want to know what you would do ifyou had a
choice.
For example, if I ask you whether you would prefer spending
one year in your current state of health or one year in excellent
health, you would probably answer one year in excellent health.
(Interviewer: 'indifferent' or 'don't care' means that the
respondent cannot decide because he/she sees the two options as
equal, not that he/she does not understand or refuses to answer the
question).
Now please tell me which you would prefer:
Living 1 year in your current state of health, living 11 months in
excellent health, or do you consider the two choices equal?
1 year in current health
- 11 months in excellent health
Equal (indifferent, no preference)
How about:
1 year in current health
9 months in excellent health
Equal (indifferent, no preference)
How about:
1 year in current health
6 months in excellent health
Equal (indifferent, no preference)
How about:
1 year in current health
3 months in excellent health
Equal (indifferent, no preference)
How about:
- 1 year in current health
1 month in excellent health
Equal (indifferent, no preference)
@ Cancer Research Campaign 1998 British Journal ofCancer(1998) 77(6), 985-991